Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05968326 · ClinicalTrials.gov registry record · Phase 2
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
A Phase 2 study of Adenocarcinoma, Pancreatic Ductal, sponsored by Genentech.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 260
- Enrollment target
- 20
- Study locations
NCT05968326 is a Phase 2 study of Adenocarcinoma, Pancreatic Ductal that is actively recruiting participants, run by Genentech. The registered enrollment target is 260 participants. The trial reports 20 study locations across 10 states.
The verdict
NCT05968326, a Phase 2 study of Adenocarcinoma, Pancreatic Ductal, is actively recruiting participants, sponsored by Genentech.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 260 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in participants with resected pancreatic ductal adenocarcinoma (PDAC) who have not received prior systemic anti-cancer treatment for PDAC and have no evidence of disease after surgery.
Conditions Studied
Interventions
- DRUG Atezolizumab
- DRUG mFOLFIRINOX
- DRUG Autogene cevumeran
Study Locations (20)
California
- USC Norris Comprehensive Cancer Center - Los Angeles
- USC Norris Cancer Center - Newport Beach
- University of California, San Francisco (UCSF) - San Francisco
- University of California Los Angeles - Santa Monica
Connecticut
- St. Francis Hospital and Medical Center - Hartford
- Smilow Cancer Center - New Haven
- Yale Cancer Center - New Haven
- Smilow Cancer Hospital Care Center at Trumbull - Trumbull
New Jersey
- Memorial Sloan Kettering Cancer Center Basking Ridge - Basking Ridge
- Memorial Sloan Kettering Cancer Center - Middletown
- Memorial Sloan Kettering Cancer Center at Bergen - Montvale
Massachusetts
- Harvard Medical School - Massachusetts General Hospital (MGH) - Cancer Center - Boston
- Boston Medical Center (BMC) - Cancer Care Center - Boston
New York
- Memorial Sloan Kettering Cancer Center - Commack - Commack
- Memorial Sloan Kettering Cancer Center at Westchester - Harrison
Illinois
- Northwestern Memorial Hospital - Chicago
Indiana
- Indiana University Health Melvin & Bren Simon Cancer Center - Indianapolis
Kentucky
- University of Kentucky Medical Center - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2023-10-18 |
| Est. Completion | 2031-01-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05968326
The ClinicalTrials.gov registry entry for NCT05968326 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 260 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Adenocarcinoma, Pancreatic Ductal appearing as the primary indexed condition, and to 3 interventions - of which Atezolizumab is the first listed.
NCT05968326 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Connecticut, New Jersey.
Frequently Asked Questions
What is clinical trial NCT05968326 about?
NCT05968326 is a clinical study titled "A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC". The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in participants with resected pancreatic ductal adenocarcinoma (PDAC) w...
What is the current status of trial NCT05968326?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 260 participants. The study started on 2023-10-18. Estimated completion is 2031-01-01.
What conditions does trial NCT05968326 study?
This clinical trial studies the following conditions: Adenocarcinoma, Pancreatic Ductal.
What interventions are being tested in trial NCT05968326?
The interventions under investigation include: Atezolizumab (DRUG), mFOLFIRINOX (DRUG), Autogene cevumeran (DRUG).
Who is sponsoring clinical trial NCT05968326?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05968326 being conducted?
This trial has 20 study locations across California, Connecticut, Illinois, Indiana, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.